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Available online 27 May 2016Autism spectrum disorders affect millions of individuals worldwide, but their heterogeneity complicates thera-
peutic intervention that is essentially symptomatic. A versatile yet relevant model to rationally screen among
hundreds of therapeutic options would help improving clinical practice. Here we investigated whether neurons
differentiated from pluripotent stem cells can provide such a tool using SHANK3 haploinsufﬁciency as a proof of
principle. A library of compounds was screened for potential to increase SHANK3mRNA content in neurons dif-
ferentiated from control human embryonic stem cells. Using induced pluripotent stem cell technology, active
compounds were then evaluated for efﬁcacy in correcting dysfunctional networks of neurons differentiated
from individuals with deleterious point mutations of SHANK3. Among 202 compounds tested, lithium and
valproic acid showed the best efﬁcacy at corrected SHANK3 haploinsufﬁciency associated phenotypes in cellulo.
Lithium pharmacotherapy was subsequently provided to one patient and, after one year, an encouraging de-
crease in autism severity was observed. This demonstrated that pluripotent stem cell-derived neurons provide
a novel cellular paradigm exploitable in the search for speciﬁc disease-modifying treatments.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under1. Introduction
Autism spectrum disorders (ASD) are a heterogeneous group of
neurodevelopmental disorders that affect 1% of the population in devel-
oped countries and are characterized by persistent impairment in recip-
rocal social communication and restricted repetitive patterns of
behavior (Newschaffer et al., 2007). Challenges in developing efﬁcient
pharmacotherapies for ASD reside in the limited understanding of ASD
etiology, the difﬁculties to experimentally model the disease, the het-
erogeneity of symptoms and the large variety of potential triggers.
Nonetheless, in around a third of patients a genetic cause has been iden-
tiﬁed (Kumar and Christian, 2009) and there appears to be a conver-
gence on mechanisms controlling synaptic homeostasis and neuronal
connectivity (Kumar and Christian, 2009; Toro et al., 2010; Bourgeron,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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get to develop new therapeutic strategies for ASD (Spooren et al., 2012;
Delorme et al., 2013). Improved understanding of the molecular sub-
strates of autism is raising the hope of innovative “disease-modifying”
treatments for altering the course of the disorder.
However, while resulting in similar pattern core of symptoms, the
synaptic/connectivity alterations in individuals with ASD show a con-
siderable degree of heterogeneity, whichmay mask the potential bene-
ﬁcial effects of a tested treatment if it is not addressed properly to a
subgroup of individuals stratiﬁed on the basis of the affected genes or
pathways rather than on the clinical phenotype per se (Delorme et al.,
2013). This pleads for the design of new experimental and pre-clinical
models to identify more personalized pharmacotherapies, approaches
that require an access to relevant cellular models and tools that would
allow analyzing at high throughput the effects of potential therapeutic
compounds on human neurons.
In this light, we have previously shown that glutamatergic cortical
neurons can be speciﬁcally differentiated from pluripotent stem cells
(PSC) of either embryonic origin (human embryonic stem cells, hESC)
or reprogrammed from somatic cells of patients with ASD caused by
SHANK3 haplo-insufﬁciency (human induced pluripotent stem cells,
hiPSC), and that they can serve as a cellular paradigm for high through-
put screening (HTS) campaigns (Boissart et al., 2013). Permitting the
systematic comparison of hundreds of small molecules in parallel, this
can therefore accelerate identiﬁcation of therapeutic compounds
targeting pathophysiological mechanisms underlying distinct forms of
ASD. The goal of thepresent studywas to verify such a strategy by focus-
ing on SHANK3 a key autism risk gene that codes for a synaptic scaffold-
ing synaptic protein.
The synaptic protein SHANK3 has been linked to autism in different
genetic screenswhere deleteriousmutations affecting the SHANK3 gene
were present in 0.69 to 2.12% of individuals (Durand et al., 2007;
Leblond et al., 2014). SHANK3 is an abundant component of the post-
synaptic density (PSD) where it acts as a scaffolding protein recruiting
key post-synaptic elements, such as glutamate receptors, and linking
them to the actin cytoskeleton (Boeckers et al., 2002). This scaffolding
role contributes to the formation, stabilization and strengthening of
the glutamatergic synapses and increases the efﬁciency of the gluta-
matergic transmission (Grabrucker et al., 2011). SHANK3 Knock-Out
mice recapitulate some key autistic behaviors and show reduced num-
ber and activity of glutamatergic synapses as well as loss in experi-
ence-linked plasticity (Peca et al., 2011). At the cellular level, neurons
differentiated from iPSC derived from individuals with SHANK3
haploinsufﬁciency, exhibit impaired electrophysiological responses to
glutamatergic synapse stimulations that can be corrected by re-intro-
ducing SHANK3 cDNA expression (Shcheglovitov et al., 2013). De-
creased glutamatergic neurotransmission thus appears as a central
feature of SHANK3 haploinsufﬁciency and it can be reversed by restor-
ing correct dosage of SHANK3 even during adulthood (Toro et al.,
2010). In individuals with ASD, de novo loss-of-function mutations of
SHANK3 reported in the literature affect only one allele of the gene, of-
fering the opportunity to enhance transcription of the second allele, or
improve mRNA stability and translation. We have therefore developed
a high throughput molecular screening assay in order to pinpoint com-
pounds increasing SHANK3 mRNA levels in human neurons derived
from pluripotent stem cells.
2. Methods
2.1. Human Pluripotent Stem Cells (hPSC) Origin
One hESC and 4 iPSC lines were used in this study. The male hESC
line SA001 was obtained from Cellartis (Goteborg, Sweden). The work
involving hESC line was supervised by the French Bioethics Agency
(Agreement number NOR AFSB 12002 43S). The control iPSC line 1869
was published previously (Boissart et al., 2013) and reprogrammedfrom ﬁbroblasts obtained from the Coriell's biorepository (Coriell Insti-
tute for Medical Research, NJ, USA). The control line PB12 was
reprogrammed from PBMC obtained from an anonymous blood donor
at the French Blood Donor Organization. SHANK3-iPSC lines were de-
rived from ﬁbroblasts of 2 children with ASD carrying independent de
novo SHANK-3 mutations. The 2 patients were diagnosed with autism
and severe intellectual deﬁciency at the Robert Debré and Pitié-
Salpétrière Hospitals according to DSM-IVTR criteria. Patient 1 (AUN-
003, Leblond et al., 2014) carries a de novo truncating mutation
P.Glu809X in exon 21 and corresponds to iPSC line SHANK3-STOP. Pa-
tient 2 carries a frame shift mutation (c.3853_3857dup, p. Gly1287Alafs
X15) and corresponds to the iPSC line SHANK3 frame-shift. Both were
included initially in a national observational study (IDRCB 2008-
A00019-46). After patient's legal representatives approval, 8-mm skin
punch biopsies were obtained (study approval by Committee for the
Protection of Persons, CPP no. C07-33). Fibroblasts were derived from
the donated tissue and reprogrammed using the four human genes
OCT4, SOX2, c-Myc, and KLF4 cloned in Sendai viruses (Life Technologies,
Carlsbad, CA, USA) and iPSC lines characterized according to Nakagawa
et al. (2008). The same procedurewas used to reprogrammed and char-
acterized control iPSC lines.
2.2. Derivation of Cortical Neural Stem Cells (NSC) from PSC
Commitment of PSC to the neural lineage and derivation of stable
cortical NSCwas described previously (Boissart et al., 2012, 2013). Brief-
ly, neural commitment was induced using the BMP inhibitor Noggin
(500 ng/ml, Peprotech, London, UK) and the Nodal inhibitor SB431542
(20 μM, Tocris Biosciences, Ellisville, Missouri, USA). At day 10, neural
rosettes containing neuro-epithelial cells were collected and plated en
bloc in poly-L-ornithin/laminin treated culture dishes in N2B27medium
containing Epidermal Growth Factor (EGF, 10 ng/ml, Peprotech, Neuilly,
France), FGF-2 (10 ng/ml, Peprotech) and Brain-derived Growth Factor
(BDNF, 20 ng/ml, Peprotech). At conﬂuence, the passages were per-
formed using trypsin at a density of 50,000 cells/cm2. Mass ampliﬁca-
tion was performed until passage 8 and cells were frozen. To start the
terminal differentiation as post-mitotic neurons, cortical NSC were dis-
sociated and plated in N2B27 without growth factors.
2.3. Compound Library
Two hundred and two small molecules were investigated, belonging
to two commercially available libraries (Screen-Well® Kinase Inhibitor
library, Enzo-life Sciences, 76 compounds and Screen-Well® Epige-
netics library, Enzo-life Sciences, 43 compounds), I-stem laboratory ref-
erence compounds (Boissart et al., 2013, 50 compounds) and FDA
approved drugs or related active principle (33 compounds). The com-
plete list of compounds is provided in Table S1.
2.4. Automated and High Throughput Quantiﬁcation of SHANK3 mRNA in
Human Neurons
To start cortical neuron differentiation, NSC were dissociated and
plated in N2B27 at a density of 6000 cells/wells in poly-L-ornithin/lam-
inin pre-treated 384 well plates using the Bravo™ automated liquid
handling platform equipped with a 384 pipette head (Agilent Technol-
ogies Inc., Santa-Clara, CA, USA). Half of the medium was changed
twice a week. In those conditions, neuronal differentiation is achieved
after 11 to 14 days. Kinetic of SHANK3 mRNA expression was
established to determine the best time point to perform the screening
(Fig. S1) and day 14 was chosen since it offered the best dynamic
range to quantify increase in SHANK3 mRNA expression. At day 14,
compounds to be tested were added using the same platform in four
replicates. The development and validation of the automated high
throughput PCR assay by itselfwas performed following published stan-
dards for qPCR based HTS (Bittker, 2012). mRNAs were extracted and
Fig. 1. SHANK3 screening results. a) Screening work ﬂow. b) Screening success rate. Among 202 molecules, 29 primary hits (increase of at least 30% of expression of the DMSO-treated
wells which correspond to a statistical deviation of more than 2 σ) were identiﬁed. Independent re-testing conﬁrmed 22 compounds. Dose response experiments revealed a
concentration-dependent mode of action for 15 compounds. Among this list of 15 compounds, 6 were chosen for further investigation. c) Table summarizing the name of the 15
compounds demonstrating a dose-dependent effect on up-regulating SHANK3 mRNA, their known biological target or medical application and their performance in the primary
screening. Results are presented as the mean fold-change values compared to DMSO treated cells and standard deviations (SD) of the 4 biological replicates. The 6 compounds chosen
for further investigation are in red.
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ogy (FastLane Cell Multiplex Kit, Qiagen, Courtaboeuf, France) with
minor modiﬁcations. A duplex qPCR strategy was used, consisting in
amplifying and quantifying both SHANK3 and the house keeping gene
PeptidylProlyl Isomerase A (PPIA) in the same well (QuantiFast Probe
Assay DP Kit). The robustness of this method was evaluated by
performing it in 66 technical replicates. Ct values were consistent be-
tween technical replicates with minimal inter-well variations (Fig. S1).
In order to evaluate the sensitivity of the duplex TaqMan PCR to
SHANK3 mRNA level modiﬁcations, SHANK3 speciﬁc shRNAs were
used to artiﬁcially decrease the level of transcripts in PSC-derived neu-
rons. Sister neuronal cultures were nucleofected (Amaxa, Lonza,
Amboise, France) with non-targeting shRNAs as controls. The perfor-
mance of the simplex method was compared with the automated du-
plex Taqman qPCR strategy and both strategies found equally efﬁcient,
indicating than automation and multiplexing had not compromised
the sensitivity and speciﬁcity of the assay (Fig. S1). Finally, the dynamics
of SHANK3mRNA synthesiswas analyzed in order to estimate a relevant
duration of treatment with the tested compounds. Neurons were treat-
ed with 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) dur-
ing 48 h to block mRNA production (Fig. S1 Sehgal et al., 1976).
Treatment with 100 μM of DRB decreased SHANK3 mRNA content by
63%. After 24 h of release from DRB, SHANK3mRNA contents were par-
tially reconstituted and reached 80% of the non-treated cells. Neurons
were, therefore, treated over 24 h for drug screening. Theﬁnal screening
workﬂow is summarized in Fig. 1a. Fold change variations induced by
compound treatments were calculated using the 2ΔCt method with
DMSO-treated cells as controls and PPIA as the reference gene.2.5. Automated Image-based High Content Screening
For high-content screening assays, cellswere ﬁxed in 4% paraformal-
dehyde for 15 min at 4 °C. Primary antibodies (Table S2) diluted in
blocking buffer were applied overnight at 4 °C. Hoechst 33,258 (2 μg/
ml, Sigma) and secondary antibodies conjugated to Alexa ﬂuorophores
(Molecular Probes, Eugene, Oregon, United States) were diluted at
1:1000 in blocking buffer and applied for 2 h at room temperature. To
quantify synapses, image acquisition and analyses were performed
using the ImageXpress® Micro XLS system (Molecular Devices, Sunny-
vale, CA, USA). A presynaptic marker and a postsynaptic marker were
used andmultiplexedwith the neuronalmarkers HuC/D and beta III Tu-
bulin (anti-Tuj-1 antibodies) to identify neurons and create a “neurite”
mask. An algorithm was then generated using MetaXpress™ software
application modules in order to identify pre- and post-synaptic spots
speciﬁcally located on neurites, then to count the number of spot co-lo-
calization (considered as synapses). Results were expressed as the den-
sity of spots for 100 μm of neurite. A minimum of 10 sites per well
(approximately 2000 neurons) was analyzed. For neuritic network pa-
rameter analysis, image acquisition was performed using Cellomics
Arrayscan system (Thermoﬁscher Scientiﬁc, Waltham, MA, USA).
Beta-III tubulin staining was used to track neurite using “Neuronal pro-
ﬁling” bioapplication as described in (Boissart et al., 2013).
2.6. Spontaneous Calcium Oscillation Recording
After 35 to 42 days of differentiation, neurons were treated during
120 h with compounds of interest in 384 well-plates. Cells were
296 H. Darville et al. / EBioMedicine 9 (2016) 293–305incubated for 10min at 37 °Cwith the Fluo-4 probe diluted at 1mM in a
loading buffer (HBSS 1X, Hepes Buffer 20 mM, pH 7.4). After 3 washes
with Mg2+-free Buffer (HBSS w/o CaCl2, w/o MgCl2, Hepes Buffer
20 mM, CaCl2 2 mM, pH = 7.4), neurons were recorded in the Mg2+-
free Buffer. The ﬂuorescence reading was performed with the
ImageXpress® Micro XLS System at 37 °C. Neurons were recorded
every second during 3min with an exposure time of 350ms. Total ﬂuo-
rescence curves were extrapolated using MetaXpress software.
2.7. Transcriptome Analysis
For transcriptome analysis of gene expression perturbations induced
by lithium and VPA, human neurons differentiated from the SA001 line
were treated during 24 h with compounds and RNA extracted using
RNAeasy extraction kit following manufacturer's instructions (Qiagen).
Fifty ng of total RNA was reverse transcribed using the Ion AmpliSeq
Transcriptome Human Gene Expression kit (Revision A.0) following
the protocol of the manufacturer (Thermo Fisher Scientiﬁc). The cDNA
libraries were ampliﬁed and barcoded using Ion AmpliSeq Tran-
scriptome Human Gene Expression core panel and Ion Xpress Barcode
Adapter (Thermo Fisher Scientiﬁc). The amplicons were quantiﬁed
using Agilent High Sensitivity DNA kit before the samples were pooled
in sets of eight. Emulsion PCR and Enrichment and loading was per-
formed on the Ion Chef Instrument using the Ion PI IC 200 Kit (Thermo
Fisher Scientiﬁc). Samples were loaded on an Ion PI v3 Chip and se-
quenced on the Ion Proton Systemusing Ion PI ICHi-Q 200Kit chemistry
(200 bp read length Thermo Fisher Scientiﬁc). The output ﬁles (FASTQ
ﬁles) were imported into the RNA-seq pipeline of Partek Flow software
(v 4.0, Partek Inc., St Louis, MO, USA) using hg19 as a reference genome.
To determine genes that are differentially expressed between groups
mapped reads were quantiﬁed using Partek E/M algorithm (the
resulting counts represent the gene expression levels for over 20,800
different genes present in the AmpliSeq Human Gene Expression
panel) and differentially expressed gene were identiﬁed using Partek
Gene Speciﬁc Analysis (GSA) algorithm. Biological interpretations of
the list of differentially expressed genes were performed using Partek
Flow v4.0 and the pathway analysis plateform EnrichR (Chen et al.,
2013).
2.8. Statistical Analyses
Data were subjected to ANOVA following by a t-test to evaluate sta-
tistical differences between cells treated with tested compounds and
DMSO-treated controls. The number of biological replicates, corre-
sponding to independent differentiations or neuronal cultures, is indi-
cated in ﬁgure legends.
3. Results
3.1. Screening of Compounds Regulating SHANK3 mRNA Expression in Hu-
man Neurons Differentiated from hESC
A collection of 202 compoundswas chosen for the primary screening
of SHANK3 regulators. This collection included a set of FDA-approved
therapeutic compounds widely used for a variety of psychiatric and
neurological diseases including epilepsy, bipolar disorders, major de-
pressive disorders or schizophrenia. It also included epigenetic regula-
tors, kinase inhibitors and compounds identiﬁed previously as
modulators of neurogenesis (Boissart et al., 2013) (Table S1).
Reprogramming of somatic cells into iPSC being potentially responsible
for induction of epigenetic and imprinting alterations that could bias the
study of gene regulation (Pick et al., 2009; Urbach et al., 2010; Lister et
al., 2011), the primary drug screeningwas conducted using neurons dif-
ferentiated from the control hESC line SA001. The 202 compoundswere
screened in 4 biological replicates at one concentration determined for
each compound based on data from the literature or from our ownpreviousﬁndings (Boissart et al., 2013;Georges et al., 2015). This prima-
ry drug screening identiﬁed 29 primary hits that increased SHANK3
mRNA content by at least 30% as compared to DMSO-treated cells and
with a deviation from the DMSO mean of more than 2 σ (Fig. 1b and
Table S1). Re-testing of these 29hits in an independent experiment con-
ﬁrmed 22 compounds (Fig. 1b). Dose-response experiments were then
conducted and revealed a concentration-dependent mode of action for
15 of them (Fig. 1b and c). Among this list of 15 compounds, 6were cho-
sen to be further investigated: 5 FDA-approved compounds (fendiline
dihydrochloride, lithium, valproic acid, aripiprazol and ﬂuoxetine) and
the 5-lipoxygenase inhibitor BWB-70C since it regulated a pathway
that can be targeted by the FDA-approved compound Zileuton. The op-
timal concentrations for each pharmacological compound were deter-
mined from the mRNA dose-response curves, and deﬁned as follows:
lithium 0.5 mM, valproic acid (VPA) 2 mM, aripiprazol 7.5 μM, ﬂuoxe-
tine 10 μM, fendiline 5 μM, BWB70C 40 μM (Fig. S2).
3.2. Modiﬁcation of SHANK3 Synaptic Content and Neuronal Activity by Hit
Compounds
The functional potential of the six drugs was ﬁrst evaluated in neu-
rons derived from the SA001 hESC line. SHANK3 protein levels and its
recruitment to the glutamatergic synapses, as well as increased gluta-
matergic activity of neuronal network were used as indicators of com-
pound efﬁcacy. The time course of synaptogenesis was analyzed by
quantifying the number of spots of the pre-synaptic protein Synapsin
and of the post-synaptic density component PSD-95 present on
neurites, a co-localization suggesting a glutamatergic synapse (Fig.
2a). In untreated hESC-derived neuronal cultures, expression of
Synapsin and PSD-95 in the neuritic compartment progressively in-
creased from day 14 to 28 and synapses were clearly present at day
28. The effects of the 6 compounds on SHANK3 synaptic content was
therefore analyzed at that later stage. In order to optimally quantify
SHANK3 protein production following treatment, cells were exposed
to compounds for at least 120 h.
Only 3 out of the 6 compounds increased SHANK3 at the protein
level in neurons at the tested concentrations, namely lithium, VPA,
and ﬂuoxetine (Fig. 2b). The same 3 compounds also signiﬁcantly in-
creased the number of neuritic sites in which SHANK3 co-localized
with PSD-95 (Fig. 2c and d; Fig. S3), suggesting an efﬁcient recruitment
at the post-synaptic density. Treatment with lithium and VPA, but not
ﬂuoxetine, increased the co-localization of SHANK3with the presynap-
tic marker Synapsin, taken as the indication of SHANK3 containing syn-
apses (Fig. 2c and d).
The relationship between the increased number of SHANK3-con-
taining synapses and functional changes in the neuronal network con-
nectivity was then investigated. At day 37, neurons were treated with
lithium,VPAorﬂuoxetine during 5 days, then network spontaneous cal-
cium oscillations (SCO), reﬂecting the number of mature synapses
(Dravid and Murray, 2004; Cao et al., 2015), were measured using
Fluo-4 calcium probe (Fig. 3). Lithium and VPA, but not ﬂuoxetine, in-
creased both SCOs frequency and intensity in treated cortical neurons
in a statistically signiﬁcant manner indicating increased network con-
nectivity. This effect was strongly decreased (VPA) or totally lost (lithi-
um) in neurons in which shRNAs targeting SHANK3 were expressed,
conﬁrming that the effects of the drugs were dependent on SHANK3
(Fig. 3).
3.3. mRNA Proﬁling Following VPA and Lithium Treatments
In order to document more generally the effect of lithium and VPA
on synaptic mRNAs, expression proﬁle of 150 neuronal and synaptic
genes was established after treatment of SA001-derived neurons by
lithium or VPA (Fig. 4a and Table S3). Lithium exerted a discrete effect
with only 16 genes up-regulated in the same range as SHANK3, i.e.
with a fold change compared to DMSO of more than 1.4, none of them
Fig. 2. Effect of hit compounds on SHANK3 protein expression and synaptic location. a) Time course analysis of synapse formation in hESC-derived developing neurons. Results are
expressed as mean ± SD of 3 independent neuronal cultures (biological replicates, left panel). Representative images of the pre-synaptic marker Synapsin (green) and the post-
synaptic marker PSD-95 (red) are shown on the right panels. Arrow indicates example of co-localization of PSD-95 and Synapsin signaling structural synapses. b) Quantiﬁcation of
SHANK3 protein expression on dendrites after treatment with hit compounds. Results are expressed as mean ± SD of 6–8 independent neuronal culture/ treatment (biological
replicates) and as fold change compared to DMSO-treated cells. * p b 0.01 t-test c) Quantiﬁcation of SHANK3 protein co-localization with synapsin and PSD-95 after compound
treatment. Results are expressed as fold change of DMSO treated cells (mean ± SD, 6–8 biological replicates par treatment). d) Representative image of SHANK3 (green) co-
localization with synapsin (red). Scale bar = 50 μm.
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rect or indirect partners of SHANK3 at the synapse, namely, the PSDpro-
tein HOMER2, the metabotropic glutamate receptors GRM1, GRM3 and
GRM6, the NMDA receptor sub-unit NR4A1 and the metalloprotease
MMP-9. The 10 additional genes were neurotrophins (NTF3 and NTF4),
GABA transporters (SLC6A12 and SLC6A13), one purinergic receptor(P2RX7), interleukin IL1B, arginine vasopressin AVP, NO synthase NOS-
1 and two protein kinases (PRKG1 and PRKCG). In contrast, VPA pro-
foundly modiﬁed synaptic mRNAs content with more than 60% of the
genes being up-regulated above 1.5 fold as compared to DMSO, and
up to 34 fold changes. This discrete effect of lithium on gene expression
was further conﬁrmed by global transcriptomic analysis. Whole
Fig. 3. Functional analysis of neuronal network activity following compounds treatment. a–b) Quantiﬁcation of spontaneous calcium oscillations (SCO) frequency (spikes/min, a) and
intensity (FAU: Fluorescence Arbitrary Units, b) in neurons treated with DMSO, ﬂuoxetine, lithium and valproic acid (VPA). SCO were recorded over a period of 180 s, results represent
mean ± SD of 5–6 biological replicates/treatment. *p b 0.01 t-test compared to DMSO treated cells. shRNA: neurons stably expressing a cDNA coding for a SHANK3 shRNA c)
Representative example of recordings.
298 H. Darville et al. / EBioMedicine 9 (2016) 293–305genome RNA sequencing revealed that only 331 genes were modiﬁed
by lithium treatment in SA001 neurons (Fold change N+1.5 or −1.5
compared to DMSO treated neurons, p b 0.05). In contrast, VPA treat-
ment induced the dysregulation of 2161 genes in the same range (Fig.
4b, c and Table S4).
3.4. Up-regulation of SHANK3 mRNA is dependent of HDAC inhibition but
independent on GSK-3 inhibition
Candidate signaling pathways potentially linking VPA and lithium to
SHANK3 up-regulation were further investigated. The way each one ofthese pharmacological agent exerts its therapeutic activity on neuronal
cells is not fully understood since both are suggested to inhibit a large
variety of enzyme-dependent cascades (Gould et al., 2004).We therefor
decided to investigate commonly targeted signaling pathways. Lithium
and VPA are considered as twomood stabilizers sharing at least two im-
portant common cellular targets: theGlycogen Synthase Kinases of type
3 (GSK-3) and class I HistoneDeacetylases (HDAC) (Wu et al., 2013; Lee
et al., 2015; Chen et al., 1999). Involvement of these two pathways in
SHANK3 mRNA regulation was investigated by treating SA001-derived
neurons using Trichostatin A, a potent and selective HDAC inhibitor, or
CHIR99021 a selective GSK-3 inhibitor (Fig. 4d). After 24 h of treatment,
Fig. 4.Molecular targets of VPA and Lithium inhuman neurons. a) Heatmap of gene expression proﬁles of 150 genes involved in synaptic plasticity or GABA/glutamate pathways inDMSO
(column 1), lithium (column 2) or valproic acid (VPA, column 3) treated neurons. FC: Fold change of mRNA expression when compared to DMSO-treated cells. b) Volcano plots showing
the distribution of differentially expressed genes in neuronal cultures treatedwith Lithium or VPA compared to DMSO (p value GSA test b0.05). Results represent mean of 3 independent
neuronal cultures per treatment. c) Venn's Diagram illustrating genes independently or commonly targeted by lithium and VPA treatments. d) Effect of inhibitors of GSK-3 (CHIR 99021)
and HDAC (Trichostatin A) dependent pathways on SHANK3mRNA expression. SHANK3mRNA levelswere quantiﬁed 24 h after treatmentwith 5 or 10 μMof the indicated inhibitor. PPIA
was used as a reference gene. Results are expressed as fold change compared to DMSO treatment (0 μM) and represent mean ± SD of 4 independent neuronal cultures per treatment. *
p b 0.05.
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300 H. Darville et al. / EBioMedicine 9 (2016) 293–305Trichostatin A signiﬁcantly increased SHANK3 mRNA. In contrast,
CHIR99021 was not able to mimic the effect of lithium and VPA on
SHANK3mRNA. In parallel, RNA sequencing data indicated that lithium
and VPA commonly up-regulated 12 genes while down-regulating 149
(Fig. 4c, Table S4). This list of gene was further investigated using the
pathway enrichment analysis tool PANTHER (Protein ANalysis THrough
Evolutionary Relationships) via EnrichR. Commonly regulated genes didnot cluster into signaling pathways linked toGSK-3 or anymetabolic en-
zymes directly targeted by lithium or VPA. In contrast, among the 149
down-regulated genes, 5 histone isoforms were identiﬁed (HIST1H1B,
HIST1H1C, HIST1H2B, HIST1H4A, HIST1H4D, Table S4). Together, this
suggested that lithium and VPA-mediated increase of SHANK3 mRNA
levels could be triggered via an epigeneticmechanism involving histone
regulation.
301H. Darville et al. / EBioMedicine 9 (2016) 293–3053.5. Lithium and VPA Action on Neurons Differentiated from iPSC of Patients
with SHANK3 Mutations
To evaluate compounds efﬁcacy on SHANK3 haplotypes associated
phenotypes, iPSC lines were derived from two children with autism
and severe intellectual disabilities who carried two different deleterious
mutations in one allele of SHANK3 (SHANK3-STOP and SHANK3 frame-
shift, Fig. S4 and Leblond et al., 2014). The two mutations were predict-
ed to lead to loss of function of one of the two alleles of SHANK3, leaving
one functional allele. Neurons were ﬁrst differentiated and compared to
neuronal cultures differentiated from two control lines PB12 and 1869
(Fig. 5 and Fig. S4). As described previously, SHANK3 haplo-insufﬁcien-
cy did not signiﬁcantly inﬂuence the rate of neuronal differentiation as
determined by quantifying the fraction of the cells expressing the neu-
ronal speciﬁc proteins HuC/D (Fig. S4) or NeuN (Fig. 5a and e) and
Tuj-1 (Fig. 5e). After 28 days of differentiation, all the culture contained
more than 70% of post-mitotic neurons independently of the presence
or absence of SHANK3 haplo-insufﬁciency. In parallel, the fraction of di-
viding neuronal precursors, characterized by the co-expression of Sox2
and Ki67 were lower than 10% (Fig. S4). SHANK3 haplo-insufﬁciency
did not modify the type of neurons produced that were mostly gluta-
matergic neurons, expressing vGlut-1/2 (Fig. 5b and f), of the superﬁcial
cortical layers (expressing the layer speciﬁc marker Cux1, Fig. 5b and
Fig. S4, Boissart et al., 2013; Yi et al., 2016). Neuronal phenotypes previ-
ously associated with SHANK3 loss of function were then deeply ana-
lyzed to determine whether they were robustly recapitulated in
neurons differentiated from iPSC of patients with disruptive point mu-
tation in SHANK3 gene. Neuritic network morphology was analyzed
by automatically tracking neurite using beta-III tubulin staining (anti-
Tuj-1 antibodies, Fig. 5c and e). Analysis of two different neuritic net-
work parameters, i.e. the size of the neuritic network associated with
a single neuron (neurite length by neuron) and the way this neuritic
network develop complexity (branching point number per neuron) in-
dicated that SHANK3 haplo-insufﬁciency impacted signiﬁcantly neurite
branching (Fig. 5c and e). Quantiﬁcation of the density of SHANK3 spots
on neurites conﬁrmed that SHANK3 haploinsufﬁciency was associated
with lower SHANK3 expression at synaptic sites since the density was
signiﬁcantly lower in the neuronal cultures differentiated from the
two SHANK3 mutated iPSC lines (Fig. 5d, g). Together, this led to deﬁ-
cient neuronal connectivity as revealed by decreased intensities and fre-
quencies of SCOs recorded in the two patient-derived neuronal cultures
after 42 days of differentiation (Fig. 5h, i).
The recapitulation of SHANK3 deﬁciency associated phenotypes in
neurons of patients with disruptive point mutations allowed us to use
them as a biological support to test the efﬁciency of VPA and lithium.
Neuronswith SHANK3mutationswere treatedwith VPAor lithiumdur-
ing 120 h. The two drugs had only a slight effect on neurite branching
(Fig. 6a) but signiﬁcantly increased the number of SHANK3-containing
synapses (Fig. 6b, d) as well as SCOs frequency and intensity in the
two SHANK3 genetic backgrounds (Fig. 6c, e). This suggested thatFig. 5.Neurons differentiated from patientswith SHANK3mutations recapitulate cellular pheno
(NeuN/Tuj-1 double positive cells) per ﬁeld of 330 μm2, in control (1869 and PB12) and SHANK
at least 6 independent differentiations,with aminimum10ﬁelds per culture. b)Quantiﬁcation o
cells. vGlut1/2 expression indicated glutamatergic neurons and Cux-1 expressionmarked cortic
differentiations. c) Quantiﬁcation of neuritic network parameters in control (iPSC 1869 and
neuronal cultures. Neurite total length represents the size in μm of the neuritic network assoc
neurite network complexity. Results represent mean ± SD of at least 6 independent neuronal
control (1869 and PB12) or SHANK3 mutated lines. Data are reported as the density of spots
per line. e) Representative images of the neuronal density (NeuN positive cells) and of the ne
SHANK3 neuronal cultures. Scale bar = 50 μm. f) Representative images of the v-Gluts (mixe
cultures. Scale bar = 100 μm. g) Representative images of SHANK3 spots on neurite of cont
oscillation frequency (spike/min) and intensity (F.A.U: Fluorescence Arbitrary Units), reﬂe
(SHANK3-STOP and SHANK3 frame-shift) in 42 days-old neuronal culture. Results represen
values above the two dark grey bars represent the mean ± SD of the two control lines. *: p b
calcium oscillations in control and SHANK3 neuronal cultures.these two compounds may be of beneﬁcial for patients from whom
the iPSC were derived.3.6. Clinical Assessment of Lithium Treatment on ASD Severity in a
SHANK3-STOP Patient
Patient AUN-003, from whom the iPSC line SHANK3-STOP was de-
rived (de novo truncating mutation P.Glu809X) was enrolled in 2012,
aged 12 years old, in an observational clinical study (Fig. 7, T0). She
had a severe ASD measured with the Social Responsiveness Scale (SRS,
raw score = 101, t-score = 89), the Autism Diagnosis Observational
Scale (ADOS, social affect domain raw score=23) and the AutismDiag-
nosis Interview-Revised version (data not shown). She displayed amild
intellectual disability with contrasting results on the Peabody Picture
Vocabulary Test (PPVT) (t-score: 101) and the Raven's progressive ma-
trices (RPM) (raw score = 9, t-score: b65). However, her adaptive be-
havior was below her cognitive ability based on the Vineland's
module 2 (communication domain raw score = 41) or the Global As-
sessment Scale (GAS, raw score= 30). At T0, by screening her psychiat-
ric comorbidity with the Kiddie SADS, a semi-structured interview,
patient AUN-003 had no lifetime history of Attention Deﬁcit Hyperac-
tive Disorder (ADHD) or of bipolar affective disorders (including
manic symptoms). Seven months later (Fig. 7, black arrow), she devel-
oped symptoms of mood deregulation. During several months, she
displayed major depressive symptoms followed by a hypomanic epi-
sode with mixed features. The maximum intensity of manic symptoms
was retrospectively assessed with the Young-Mania rating Scale (Y-
MRS, raw score = 26). Five months later, (Fig. 7, red arrow), facing in-
ability to control the symptoms, lithiumwas introduced as an indication
for bipolarity. Considering the in vitro results obtained on her iPSC de-
rived neurons, ASD scores were carefully assessed. After 8 months of
treatment (T1), she displayed a clear improvement onmanic symptoms
(Y-MRS raw score = 18). In addition, a modest but signiﬁcant positive
effect was identiﬁed on ASD severity, as evaluated by the SRS (raw
score=84, t-score=80), aswell as on her cognitive performancemea-
sured with the RPM (raw score= 13, t-score b 70). However, the adap-
tive behavior was not improved whatever the scale considered (GAS=
25, Vineland communication domain score = 31). After one year (T2)
adaptive behavior started to improve as compared to T1, though still
close to the performance at T0 (GAS=30, Vineland score= 35), i.e. be-
fore regression. In contrast, the caregivers reported additional reduction
of autistic symptoms on the SRS (raw score = 73, t-score = 75), which
was further conﬁrmed by results on the ADOS (social affect domain raw
score = 17). These two tests revealed that ASD symptoms were lower
than before regression. In contrast, there has been a degradation of
her ability to control her impulsivity between T1 and T2, associated to
distractibility. Caregivers mentioned that these symptoms differed
from those observed during the manic episodes. Despite their late
onset, symptoms tended to evoke clinical features of ADHD (ADHD-types associated to SHANK3haploinsufﬁciency. a) Quantiﬁcation of the number of neurons
3mutated (SHANK3 STOP and SHANK3 frame shift) lines. Results represent mean± SD of
f neuronal sub-type present in 28days neuronal culture obtained from controls or SHANK3
al glutamatergic neurons of the superﬁcial layers. Results are mean± SD of 3 independent
iPSC PB12) and SHANK3 mutated (SHANK3-STOP and SHANK3 frame shift) 28 days-old
iated with one neuron while the number of branching points quantiﬁes more speciﬁcally
cultures per line. d) Quantiﬁcation of SHANK3 synaptic content in neurons derived from
per 100 μm of neurite. Results represent mean ± SD of 4 independent neuronal cultures
uritic network revealed using beta-III tubulin staining (Tuj-1 antibodies) in control and
d antibodies recognizing v-Glut1 and vGlut-2) staining in control and SHANK3 neuronal
rol and SHANK3 neurons. Scale bar = 20 μm. h) Quantiﬁcation of spontaneous calcium
cting neuronal network activity, in control (PB12 and 1869) and in SHANK3 mutated
t mean ± SD of recording of at least 6 neuronal cultures per lines. In panel c, d and h,
0.05, control lines vs the indicated SHANK3 mutated line. i) Representative recording of
Fig. 6. VPA and Lithium treatment efﬁciency in neurons with SHANK3mutations. a) Quantiﬁcation of the number of neurite branching points of neurons derived from SHANK3mutated
lines after lithium and VPA treatments. Results represent mean ± SD of 3 independent differentiation/treatment. b) Quantiﬁcation of SHANK3 synaptic content in neurons derived from
iPSC individuals bearing the two different SHANK3mutations (SHANK3-STOP and SHANK3 frame shift) after 120 h treatment with valproic acid (VPA) or lithium. Results are presented as
fold change variations compared to DMSO-treated cells and represented as mean± SD of at least 6 independent biological replicates/treatment. c) Quantiﬁcation of spontaneous calcium
oscillation frequency and intensity in SHANK3 mutated lines (SHANK3-STOP and SHANK3 frame-shift) with or without treatment with VPA or lithium. Data represent mean ± SD of 4
independent neuronal cultures per treatment. * p b 0.01 Lithium or VPA vs DMSO. d) Representative images of SHANK3 and Synapsin expression in DMSO, VPA and Lithium treated
neurons. e) Representative recording of calcium oscillations.
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Fig. 7. Clinical assessment of patient AUN-003 (SHANK3-STOP). T0: Patient AUN-003 aged 12 years old, was enrolled in the study (2012). Black arrow: she developed symptoms of mood
deregulation and regression. Red Arrow: start of lithium treatment (0.6 mL–1000mg/d). T1: 8months follow-up, T2: one year follow-up. SRS: Social Responsiveness Scale, ADOS: Autism
Diagnosis Observational Scale, RPM: Raven's progressive matrices, PPVT: Peabody Picture Vocabulary Test, GAS: Global Assessment Scale, ADHD-RS: Attention deﬁcit associated to
hyperactivity disorder rating Scale, Y-MRS: Young-Mania rating Scale.
303H. Darville et al. / EBioMedicine 9 (2016) 293–305RS, global raw score= 25). Table S5 reports in details the scores obtain-
ed for each tests and each sub-categories.
4. Discussion
SHANK3 haplo-insufﬁciency induced by heterozygous loss of func-
tion mutations represents a clear model of abnormal gene dosage lead-
ing to ASD (Durand et al., 2007; Yi et al., 2016) that can be reversed by
genetically re-introducing SHANK3 normal levels of expression, includ-
ing during adulthood, in mice models (Shcheglovitov et al., 2013). (Mei
et al., 2016). We therefore proposed that successful therapeutic com-
pounds for SHANK3 haplo-insufﬁciency dependent form of ASD could
be identiﬁed based on their potential to up-regulate this gene in
human neurons. We ﬁrst selected potential hit compounds using con-
trol hESC derived neurons, to avoid epigenetic bias potentially induced
by iPSC reprogramming (Urbach et al., 2010; Lister et al., 2011).
Patient-derived iPSC cellular models were then used to challenge their
efﬁcacy at corrected SHANK3-associated neuronal phenotypes consid-
ered as relevant for ASD symptoms (Bozdagi et al., 2010; Yi et al.,
2016). Interestingly, among the compounds regulating SHANK3 identi-
ﬁed in the present studywere the twomood stabilizers VPA and lithium
that share common cellular targets. Additionally, we reported promis-
ing results of lithium pharmacotherapy to reduce ASD core symptoms
in one of the patient from whom iPSC were produced. Supporting our
observations, lithium was previously shown to overcome neonatal iso-
lation-induced autistic-like behavior in a rat model by restoring the
compromised balance between excitatory/inhibitory synaptic activities
(Wu et al., 2014). Lithium was also proposed as a potential therapeutic
approach for Fragile X syndrome. Chronic lithium treatment contributes
to normalized behavior and synaptic transmission in mice models of
Fragile X syndrome and pilot clinical trials have shown promising re-
sults in individuals with Fragile X syndrome (Liu and Smith, 2014).
This suggests that lithium may have a global positive effect on gluta-
matergic synapse genesis and homeostasis. This would be consistentwith mRNA proﬁling performed in the present study, which indicate
that lithium positively regulates SHANK3 together with 6 of its pro-
tein-partners at the glutamatergic synapse. How lithium regulates
SHANK3 remains, however, to be fully characterized as lithium acts on
a large variety of signaling pathways (Wu et al., 2013; Pasquali et al.,
2010; Millan, 2013). Our results suggest that lithium, as VPA, may act,
in part, through its HDAC inhibitory activity and regulate SHANK3 via
an epigenetic mechanism. Lithiumwas demonstrated to inhibit inositol
dependent enzymes by depleting inositol cellular content (Gould et al.,
2004). Interestingly, HDACwere recently demonstrated as depending of
inositol for proper activity (Watson et al., 2016). This suggests that Lith-
ium may directly inhibit HDAC activity via inositol depletion. In addi-
tion, we found that Lithium, as VPA, down-regulated directly histone
expression. Together, lithium and VPA may regulate SHANK3 at an epi-
genetic levels via several pathways linked to histone linkage to DNA.
Clinical assessment of patient AUN-003 suggested that lithium, initially
provided for bipolar disorders, improved also her social and interaction
behavior as evaluated using SRS and ADOS. Interestingly, after one year
of treatment, performances on SRS and ADOS were better than when
she was ﬁrst enrolled in the study 2.5 years before (T0), i.e. before the
beginning of mood deregulation. These effects on scales exploring ASD
were not correlated with performance on global adaptation behavior
scales (Vineland and GAS), suggesting that the improvement recorded
for ASD symptoms was not, at least not only due to a recovery from re-
gression or a placebo effect. While encouraging, our case report also re-
vealed the emergence of ADHD in this patient that should serve as a
cautionary tale for the premature use of this approved medication for
a complex condition such as ASD. These symptoms resembled the hy-
perkinetic, manic-like, disorders described previously in two patients
with SHANK3 duplication and mimicked in SHANK3 overexpressing
mice(Han et al., 2013). In this mouse model, lithium was inefﬁcient at
correcting SHANK3 dependent maniac-like behavior, in contrast to
VPA, an atypical pharmacological proﬁle for manic-like disorders. In
light of our results, the up-regulation of SHANK3 by lithiummay explain
304 H. Darville et al. / EBioMedicine 9 (2016) 293–305the lack of efﬁcacy. Regarding VPA, additional action of this compound
on the GABAergic system may overall result in a correction of the
manic-like behavior despite up-regulating SHANK3. Collectively, this
suggests that lithium may have improved ASD symptoms but induced
ADHD-like behavior by increasing SHANK3 in AUN-003. These observa-
tions highlight the fact that proper SHANK3 dosage is critical for normal
brain function, and warrant deeper investigation of the mechanisms of
action of lithium, VPA and related agents and their potential beneﬁts
for patients with SHANK3 haplo-insufﬁciency. Our work pleads for a
deeper characterization of instrumental pathways sustaining lithium
action on SHANK3 to identify more speciﬁc molecules and avoid poten-
tial non-desired side effects resulting from the inhibition ofmultiple cel-
lular targets not involved in SHANK3 regulation. Additionally, animal
testing will be critical to elucidate lithium efﬁcacy. So far, the most
widely studied models are mice fully knock-out for SHANK3 isoforms.
These mice exhibit strong and robust abnormal behavior (review in
Jiang and Ehlers, 2013). Consistently, validation of pharmacological ap-
proaches preferentially uses these KO mice (Bozdagi et al., 2013;
Bidinosti et al., 2016). However, our approach is based upon the identi-
ﬁcation of compounds rescuing SHANK3 associated phenotypes by in-
creasing SHANK3 mRNA levels. Testing of lithium would therefore
need to be performed in heterozygous mice with one wild-type allele.
Unfortunately, these mice develop only very speciﬁc and discrete phe-
notypes (Bozdagi et al., 2010), the robustness of which limiting their
use asmodel for testing efﬁciency of pharmacological approaches. Final-
ly, formal conclusions would come from a randomized double blind
clinical trial against placebo that will be needed to accurately validate
the effect of lithium in patients carrying SHANK3 loss of function muta-
tions and exclude any possibility of symptom improvement solely due
to change in educational care or any other environmental factors.
5. Conclusion
The main result of this study is the demonstration that lithium, the
FDA-approved drug for bipolar disorders, regulates SHANK3 expression
in a way that bears therapeutic potential for patients with ASD associat-
ed to SHANK3 haploinsufﬁciency. This result has been obtained on the
basis of a drug screening challenging molecular and functional pheno-
types relevant to the disease in neurons derived from pluripotent
stem cell lines, including from patients awaiting a treatment. This
novel methodology for drug discovery is applicable to other forms of
ASD with contrasting pathophysiological substrates, as well as to other
CNS disorderswith knownmolecular anomalies. As such, it offers an av-
enue to the stratiﬁcation of treatment and, ultimately, personalized
medicine for psychiatric disorders.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.05.032.
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